Table II.
Correlation between USP10/MSH2 expression and clinicopathological features of NSCLC.
| USP10 protein expression | MSH2 protein expression | |||||
|---|---|---|---|---|---|---|
| Clinicopathological feature | Negative, n | Positive, n (%) | P-valuea | Negative, n | Positive, n (%) | P-valuea |
| Sex | ||||||
| Male | 58 | 43 (42.57) | 0.81 | 13 | 77 (85.56) | 0.085 |
| Female | 26 | 21 (44.68) | 12 | 33 (73.33) | ||
| T stage | ||||||
| T1 | 31 | 29 (48.33) | 0.601 | 9 | 43 (82.69) | 0.553 |
| T2 | 35 | 23 (39.66) | 15 | 39 (72.22) | ||
| T3 | 9 | 4 (30.77) | 2 | 9 (81.82) | ||
| T4 | 9 | 8 (47.06) | 3 | 15 (83.33) | ||
| N stage | ||||||
| N0 | 58 | 45 (43.69) | 0.868 | 17 | 79 (82.29) | 0.974 |
| N1/N2/N3 | 26 | 19 (42.22) | 7 | 32 (82.05) | ||
| M stage | ||||||
| M0 | 82 | 64 (43.84) | − | 29 | 103 (78.03) | − |
| M1/M2/M3 | 2 | 0 (0) | 0 | 3 (100) | ||
| TNM | ||||||
| I | 47 | 35 (42.68) | 0.394 | 14 | 62 (81.58) | 0.186 |
| II | 13 | 15 (53.57) | 3 | 18 (85.71) | ||
| III/IV | 24 | 14 (36.84) | 12 | 26 (68.42) | ||
| Differentiationb | ||||||
| Well | 18 | 13 (41.94) | 0.739 | 8 | 19 (70.37) | 0.287 |
| Moderate | 35 | 30 (46.15) | 11 | 48 (81.36) | ||
| Poor | 24 | 15 (46.15) | 5 | 31 (86.11) | ||
| Age, years | 59.76±8.34 | 60.22±8.04 | 0.738c | 58.59±8.2 | 59.86±8.06 | 0.454c |
| Diameter, cm | 4.47±2.03 | 4.09±2.32 | 0.29c | 4.38±1.93 | 4.44±2.35 | 0.895c |
a
χ2 or Fisher's exact test.
b
For USP10 protein, there were 31 well-differentiated cases, 65 cases of moderate differentiation, 39 cases of poor differentiation, and 13 other cases among the 148 patients with NSCLC. For MSH2 protein, there were 27 well-differentiated cases, 59 cases of moderate differentiation, 36 cases of poor differentiation, and 13 other cases among 135 cases of patients with NSCLC.
c
Student's t-test. MSH2, MutS homolog 2; USP10, ubiquitin-specific protease 10; NSCLC, non-small cell lung cancer; TCGA, The Cancer Genome Atlas; TNM, Tumor-Node-Metastasis.